Use of galactomannan to produce hydrophilic matrix tablets

E. Berta, K. Pintye-Hódi, P. Szabó-Révész, M. Miseta, B. Selmeczi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Galactomannan currently seems to be a very promising auxiliary. The aim of the present work was to examine the applicability of this auxiliary in tablet-making. Galactomannan is a polysaccharide composed of galactose and mannose, which is distributed by the Swiss firm Meyhall under the name Meyprogat. The products are numbered according to their molecular weight and polymeric degree. Thus, Meyprogat 7, 30, 60, 90, 120 and 150 can be discriminated. It is used in many areas, for example in the food industry as a stabilizing agent, and in medical therapy to cure diabetes and hyperlipidaemia. In pharmaceutical technology, it is used in low concentration (5-10%) as a disintegrant agent and in high concentration (25%) as binding agent. It is able to form a hydrophilic matrix, which results in sustained release. Theophylline was chosen as model agent. After the preformulation examinations, granulations were made by a wet method, and after this, tablets were formed. Examinations were made of the granulations, the physical parameters of the tablets were determined, and the release of the effective agent from the tablets was studied. The following conclusions were drawn: 1. Galactomannan yields tablets with very good hardness. 2. Galactomannan is suitable for the formation of hydrophilic matrix tablets. Through use of this macromolecular agent, the rate of dissolution can be influenced in accordance with the desired purpose. Under in vitro circumstances, within 7 hours total and uniform dissolution can be achieved if Meyprogat 150 is used as a 5 percent gel as granulating liquid. In this case, the galactomannan content of the tablets is 14.12%. If it is used as a powder, a tablet galactomannan content of 25% can be attained, which is suggested by the technical literature. However, in this case the initial rapid dissolution slows down, and within 7 hours only part of the effective agent is released. In accordance with the desired purpose, sustained release can also be achieved with products of lower molecular weight.

Original languageEnglish
Pages (from-to)26-29
Number of pages4
JournalActa Pharmaceutica Hungarica
Volume64
Issue number1
Publication statusPublished - 1994

Fingerprint

Tablets
Molecular Weight
Pharmaceutical Technology
galactomannan
Excipients
Food Industry
Hardness
Theophylline
Mannose
Hyperlipidemias
Galactose
Powders
Names
Polysaccharides
Gels

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Use of galactomannan to produce hydrophilic matrix tablets. / Berta, E.; Pintye-Hódi, K.; Szabó-Révész, P.; Miseta, M.; Selmeczi, B.

In: Acta Pharmaceutica Hungarica, Vol. 64, No. 1, 1994, p. 26-29.

Research output: Contribution to journalArticle

@article{e3dfb6304d1748dd86ead3aac6660482,
title = "Use of galactomannan to produce hydrophilic matrix tablets",
abstract = "Galactomannan currently seems to be a very promising auxiliary. The aim of the present work was to examine the applicability of this auxiliary in tablet-making. Galactomannan is a polysaccharide composed of galactose and mannose, which is distributed by the Swiss firm Meyhall under the name Meyprogat. The products are numbered according to their molecular weight and polymeric degree. Thus, Meyprogat 7, 30, 60, 90, 120 and 150 can be discriminated. It is used in many areas, for example in the food industry as a stabilizing agent, and in medical therapy to cure diabetes and hyperlipidaemia. In pharmaceutical technology, it is used in low concentration (5-10{\%}) as a disintegrant agent and in high concentration (25{\%}) as binding agent. It is able to form a hydrophilic matrix, which results in sustained release. Theophylline was chosen as model agent. After the preformulation examinations, granulations were made by a wet method, and after this, tablets were formed. Examinations were made of the granulations, the physical parameters of the tablets were determined, and the release of the effective agent from the tablets was studied. The following conclusions were drawn: 1. Galactomannan yields tablets with very good hardness. 2. Galactomannan is suitable for the formation of hydrophilic matrix tablets. Through use of this macromolecular agent, the rate of dissolution can be influenced in accordance with the desired purpose. Under in vitro circumstances, within 7 hours total and uniform dissolution can be achieved if Meyprogat 150 is used as a 5 percent gel as granulating liquid. In this case, the galactomannan content of the tablets is 14.12{\%}. If it is used as a powder, a tablet galactomannan content of 25{\%} can be attained, which is suggested by the technical literature. However, in this case the initial rapid dissolution slows down, and within 7 hours only part of the effective agent is released. In accordance with the desired purpose, sustained release can also be achieved with products of lower molecular weight.",
author = "E. Berta and K. Pintye-H{\'o}di and P. Szab{\'o}-R{\'e}v{\'e}sz and M. Miseta and B. Selmeczi",
year = "1994",
language = "English",
volume = "64",
pages = "26--29",
journal = "Acta Pharmaceutica Hungarica",
issn = "0001-6659",
publisher = "Magyar Gyogyszereszeti Tarsasag",
number = "1",

}

TY - JOUR

T1 - Use of galactomannan to produce hydrophilic matrix tablets

AU - Berta, E.

AU - Pintye-Hódi, K.

AU - Szabó-Révész, P.

AU - Miseta, M.

AU - Selmeczi, B.

PY - 1994

Y1 - 1994

N2 - Galactomannan currently seems to be a very promising auxiliary. The aim of the present work was to examine the applicability of this auxiliary in tablet-making. Galactomannan is a polysaccharide composed of galactose and mannose, which is distributed by the Swiss firm Meyhall under the name Meyprogat. The products are numbered according to their molecular weight and polymeric degree. Thus, Meyprogat 7, 30, 60, 90, 120 and 150 can be discriminated. It is used in many areas, for example in the food industry as a stabilizing agent, and in medical therapy to cure diabetes and hyperlipidaemia. In pharmaceutical technology, it is used in low concentration (5-10%) as a disintegrant agent and in high concentration (25%) as binding agent. It is able to form a hydrophilic matrix, which results in sustained release. Theophylline was chosen as model agent. After the preformulation examinations, granulations were made by a wet method, and after this, tablets were formed. Examinations were made of the granulations, the physical parameters of the tablets were determined, and the release of the effective agent from the tablets was studied. The following conclusions were drawn: 1. Galactomannan yields tablets with very good hardness. 2. Galactomannan is suitable for the formation of hydrophilic matrix tablets. Through use of this macromolecular agent, the rate of dissolution can be influenced in accordance with the desired purpose. Under in vitro circumstances, within 7 hours total and uniform dissolution can be achieved if Meyprogat 150 is used as a 5 percent gel as granulating liquid. In this case, the galactomannan content of the tablets is 14.12%. If it is used as a powder, a tablet galactomannan content of 25% can be attained, which is suggested by the technical literature. However, in this case the initial rapid dissolution slows down, and within 7 hours only part of the effective agent is released. In accordance with the desired purpose, sustained release can also be achieved with products of lower molecular weight.

AB - Galactomannan currently seems to be a very promising auxiliary. The aim of the present work was to examine the applicability of this auxiliary in tablet-making. Galactomannan is a polysaccharide composed of galactose and mannose, which is distributed by the Swiss firm Meyhall under the name Meyprogat. The products are numbered according to their molecular weight and polymeric degree. Thus, Meyprogat 7, 30, 60, 90, 120 and 150 can be discriminated. It is used in many areas, for example in the food industry as a stabilizing agent, and in medical therapy to cure diabetes and hyperlipidaemia. In pharmaceutical technology, it is used in low concentration (5-10%) as a disintegrant agent and in high concentration (25%) as binding agent. It is able to form a hydrophilic matrix, which results in sustained release. Theophylline was chosen as model agent. After the preformulation examinations, granulations were made by a wet method, and after this, tablets were formed. Examinations were made of the granulations, the physical parameters of the tablets were determined, and the release of the effective agent from the tablets was studied. The following conclusions were drawn: 1. Galactomannan yields tablets with very good hardness. 2. Galactomannan is suitable for the formation of hydrophilic matrix tablets. Through use of this macromolecular agent, the rate of dissolution can be influenced in accordance with the desired purpose. Under in vitro circumstances, within 7 hours total and uniform dissolution can be achieved if Meyprogat 150 is used as a 5 percent gel as granulating liquid. In this case, the galactomannan content of the tablets is 14.12%. If it is used as a powder, a tablet galactomannan content of 25% can be attained, which is suggested by the technical literature. However, in this case the initial rapid dissolution slows down, and within 7 hours only part of the effective agent is released. In accordance with the desired purpose, sustained release can also be achieved with products of lower molecular weight.

UR - http://www.scopus.com/inward/record.url?scp=0028182555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028182555&partnerID=8YFLogxK

M3 - Article

C2 - 8023683

AN - SCOPUS:0028182555

VL - 64

SP - 26

EP - 29

JO - Acta Pharmaceutica Hungarica

JF - Acta Pharmaceutica Hungarica

SN - 0001-6659

IS - 1

ER -